[Cyclophosphamide pulse therapy for refractory rheumatic diseases].
We studied the efficacy of cyclophosphamide pulse therapy (CYP) for refractory rheumatic diseases except for lupus nephritis. Thirty-five patients were included in all, that is 9 patients with systemic lupus erythematosus (SLE), 10 with rheumatoid arthritis (RA), 7 with polymyositis/dermatomyositis (PM/DM), 2 with progressive systemic sclerosis (PSS), 2 with anti-phospholipid antibody syndrome (APS), 1 with mixed connective tissue disease (MCTD), 1 with juvenile rheumatoid arthritis (JRA), 1 with Behcet's disease (BD), 1 with Wegener's granulomatosis (WG) and 1 with allergic granulomatous angiitis (AGA). Moderate to marked improvement was noted in 4 patients with SLE (2 with CNS-lupus and 2 with vasculitis), 7 with RA (2 with interstitial pneumonia:IP, 2 with vasculitis and 2 with refractory arthritis), 4 with PM/DM (2 with IP and 2 with refractory myositis), 1 PSS with IP, 2 APS with thrombocytopenia, 1 JRA with vasculitis and BD with CNS disturbance. On the other hand, adverse reactions were observed in 9 out of 35 patients (25.8%). CYP should apply in the treatment for such refractory rheumatic diseases as CNS disturbance, vasculitis, IP and autoimmune thrombocytopenia.
Tateishi
M
M
Institute of Rheumatology, Tokyo women's Medical College.
Taniguchi
A
A
Moriguchi
M
M
Hara
M
M
Kashiwazaki
S
S
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003882:Dermatomyositis / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008875:Middle Aged; D017285:Polymyositis / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000188:drug therapy*
D003520:Cyclophosphamide